Standardized
Glucosol™
Study In 1998, a crossover, placebo-controlled
clinical study was conducted at the Tokyo Jikeikai Medical
School in Japan with 24 subjects. The criteria for including
subjects in this study were mild case of insulin independent
diabetes, inability to tolerate glucose burden, glucose levels
of 110mg/deciliter (fasting level) and subjects older than
20 years of age.
The subjects were given orally either a placebo or 3 tablets
of 250mg each, after each meal three times daily. The daily
total dose of Corosolic acid was 0.16 mg, the active ingredient
of Glucosol™. The results of this study clearly demonstrate
that Glucosol™ is effective in reducing blood glucose
levels even in short-term (4 weeks) trea™ent, with no signs
of adverse effects.
Furthermore, even a one-time dose leaves a memory-effect for
blood glucose control. Compared to the placebo group, a statistically
significant drop in the average blood glucose level is observed
with the administration of Glucosol™ Blood glucose level
dropped from 153.9 mg/deciliter, before the Glucosol™
dose, to 133.1 mg/deciliter, after the dose.
<<<back
Copyright, 2003 - 2009 DHS, Inc. All Rights Reserved.
Reproduction of any kind is prohibited without the written permission of DHS, Inc.
|